Media

CEO and MD Dr Daniel Tillett joined ausbiz post the release of September Quarterly Activity Report, reaffirming the company’s strong funding position, clinical pipeline, and noting changes in the Board and Management team. Watch the full interview via this link.

Racura Oncology joins four other biotech companies to present at HealthInvest 2024, hosted by IR Department, Morgans and Stockhead. At the conference, Racura presented the clinical development history of its lead asset bisantrene, and the pipeline for the coming months to investors, analysts and industry peers in the room. Watch the interview with Dr Peter…

Racura Executive Chair Dr Peter Smith speaks with Proactive about the recent board changes and the company’s clinical pipeline for its lead drug asset, bisantrene. Read the full report here.

Racura Oncology is pleased to release the FY24 annual report. Key highlights include: Read the full report via this link.

Racura is pleased to be featured in Stockhead’s Investor Guide this year. The Investor Guide showcases strong forces from the Australian health and biotech sector, offering deep insights to ASX investors. In this feature, Racura CEO Dr Daniel Tillett shares the company’s journey of discovering and developing lead asset bisantrene, a unique drug for its…

Racura CEO Dr Daniel Tillett speaks with Jonathan Jackson in the Proactive studio to discuss positive results from an investigator-sponsored Phase 1b/2 trial of RC110 bisantrene for acute myeloid leukaemia (AML). Read the article here, and watch the full interview below.

The Australian reports the conclusion of Racura’s Phase 1b/2 investigator-sponsored trial of RC110 bisantrene in relapsed or refractory acute myeloid leukaemia patients, conducted at the Chaim Sheba Medical Centre in Israel and led by Professor Arnon Nagler. The results show that 40% of patients with highly advanced disease showing a response to bisantrene. Read the…

Racura Oncology Executive Director Dr Peter Smith joined Disrupt Radio to discuss building biotech businesses in Australia, what to look out for when investing in biotech businesses, and why Racura’s lead drug bisantrene is a unique asset carrying great clinical and commercial potential. You can listen to Dr Smith’s full interview via this link.